Centralized core facilities have evolved in complexity and sophistication. Today these facilities serve as our institution’s technical hub providing investigators cost effective access to both advanced technologies and resident collaborative expertise necessary to leverage these approaches. With over 17 years of core facility operations and management experience, I drive the establishment, integration and oversight of new core facilities and the importation and integration of new technologies within existing facilities. My core facilities experience both in the United States and in international institutions in Europe as well as business experience acquired founding and managing a small biotech company have enabled me monitor performance by established financial and operational metrics (accessibility, currency, quality, timeliness, cost effectiveness). In my current role, I direct the operations of thirteen centrally managed umbrella core organizations with >130 employees delivering $18M of service annually. In addition, I have successfully been making monoclonal antibodies since 1988 and have over the course of 29 years refined and adapted classical hybridoma protocols. Through the patented invention of microarray-based screening assays coupled to robotically executed cell culture I have increased the per FTE throughput of monoclonal antibody core facilities by over an order of magnitude. I have directed high throughput facilities at the European Molecular Biology Laboratory and Monash University and more recently The Jackson Laboratory (JAX). Facilities at JAX are state of the art and recent investment in equipment and manpower keeps the Monoclonal Antibody Service at the forefront of hybridoma production technology.